Patents by Inventor Chul Woo Yang
Chul Woo Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969397Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.Type: GrantFiled: November 7, 2019Date of Patent: April 30, 2024Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Dong-Yun Shin, Jong-Young Choi, Chul-Woo Yang, Sung-Hwan Park, Seon-Yeong Lee, Min-Jung Park, Joo-Yeon Jhun, Se-Young Kim, Hyeon-Beom Seo, Jae-Yoon Ryu, Keun-Hyung Cho
-
Publication number: 20240131027Abstract: The present invention relates to a pharmaceutical composition comprising a novel compound as an active ingredient for prevention or treatment of transplant rejection. The novel compound SD911 of the present invention was identified to repress the migration of immune cells, increase the engraftment and viability of a grafted tissue, and regulate immune cells. In addition, it was found in a kidney transplantation model that the compound restrained human PBMC from suppressing the engraftment and damaging renal tissues and downregulated the expression of the inflammatory cytokine IL-17, with the consequent effective prevention and treatment of transplant rejection.Type: ApplicationFiled: April 6, 2022Publication date: April 25, 2024Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Chul Woo YANG, Dongyun SHIN, Sun Woo LIM, Mi La CHO, Yoo Jin SHIN, Seon Yeong LEE, A Ram LEE
-
Publication number: 20220251155Abstract: The present invention relates to: a recombinant peptide in which a Mitochondria Localization Sequence (MLS) peptide and the Signal Transducer and Activator of Transcription 3 (STAT3) are fused to each other; a recombinant vector carrying a polynucleotide coding for the recombinant peptide; and a composition comprising the recombinant peptide or the recombinant vector as an active ingredient for prevention or treatment of autoimmune disease or inflammatory disease, wherein the recombinant peptide or the recombinant vector allows STAT3 to be overexpressed in the mitochondria to enhance the mitochondrial function, resulting in inhibiting the expression of inflammatory cytokines including IL-17, whereby the composition may be advantageously used for preventing or treating autoimmune disease or inflammatory diseases.Type: ApplicationFiled: January 28, 2020Publication date: August 11, 2022Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Sung-Hwan PARK, Seon-Yeong LEE, Su-Jin MOON, Eun-kyung KIM, Jun-Geol RYU, Si-Yeong CHOI, Jeong-Won CHOI, Kyung-Ah JUNG, A-Ram LEE, Chul-Woo YANG, Jeong-Hyeon MOON
-
Publication number: 20220064246Abstract: The present invention relates to a novel complex that is formed by linking p40 subunit and EBI3 subunit via a linker and has excellent anti-inflammatory effects and immunomodulatory effects.Type: ApplicationFiled: December 20, 2019Publication date: March 3, 2022Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Chul-Woo YANG, Sung-Hwan PARK, Seon-Yeong LEE, Young-Mee MOON, Seung-Ki KWOK, Hyeon-Beom SEO, Jun-Geol RYU, Eun-Kyung KIM
-
Publication number: 20220031637Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.Type: ApplicationFiled: November 7, 2019Publication date: February 3, 2022Inventors: Mi-La CHO, Dong-Yun SHIN, Jong-Young CHOI, Chul-Woo YANG, Sung-Hwan PARK, Seon-Yeong LEE, Min-Jung PARK, Joo-Yeon JHUN, Se-Young KIM, Hyeon-Beom SEO, Jae-Yoon RYU, Keun-Hyung CHO
-
Publication number: 20220028463Abstract: A memory device, including a plurality of planes, includes a mode setting component to set an operation mode of the memory device as a verify pass mode to allow a verify operation, performed in the plurality of planes, to forcibly pass; and a verify signal generator for outputting a verify pass signal signaling that the verify operation has passed for each of the plurality of planes.Type: ApplicationFiled: October 7, 2021Publication date: January 27, 2022Applicant: SK hynix Inc.Inventors: Tai Kyu KANG, Chul Woo YANG
-
Patent number: 11170859Abstract: A memory device, including a plurality of planes, includes a mode setting component to set an operation mode of the memory device as a verify pass mode to allow a verify operation, performed in the plurality of planes, to forcibly pass; and a verify signal generator for outputting a verify pass signal signaling that the verify operation has passed for each of the plurality of planes.Type: GrantFiled: February 20, 2020Date of Patent: November 9, 2021Assignee: SK hynix Inc.Inventors: Tai Kyu Kang, Chul Woo Yang
-
Patent number: 11049535Abstract: A page buffer includes a bit line sensing circuit, a latch, and a main latch for sensing and storing data from a memory cell. The bit line sensing circuit is coupled with the memory cell by a bit line and configured to perform a bit line sensing operation of sensing first data stored in the memory cell. The latch control circuit is coupled with the bit line sensing circuit. The main latch is coupled with the bit line sensing circuit through the latch control circuit and configured to perform a main latch operation of storing the sensed first data. The cache latch is coupled with the main latch and configured to perform a cache latch operation of storing second data stored in the main latch. Wherein a period of time of the cache latch operation overlaps with a period of time of the bit line sensing operation.Type: GrantFiled: April 20, 2020Date of Patent: June 29, 2021Assignee: SK hynix Inc.Inventor: Chul Woo Yang
-
Publication number: 20210090620Abstract: A page buffer includes a bit line sensing circuit, a latch, and a main latch for sensing and storing data from a memory cell. The bit line sensing circuit is coupled with the memory cell by a bit line and configured to perform a bit line sensing operation of sensing first data stored in the memory cell. The latch control circuit is coupled with the bit line sensing circuit. The main latch is coupled with the bit line sensing circuit through the latch control circuit and configured to perform a main latch operation of storing the sensed first data. The cache latch is coupled with the main latch and configured to perform a cache latch operation of storing second data stored in the main latch. Wherein a period of time of the cache latch operation overlaps with a period of time of the bit line sensing operation.Type: ApplicationFiled: April 20, 2020Publication date: March 25, 2021Applicant: SK hynix Inc.Inventor: Chul Woo YANG
-
Publication number: 20210027847Abstract: A memory device, including a plurality of planes, includes a mode setting component to set an operation mode of the memory device as a verify pass mode to allow a verify operation, performed in the plurality of planes, to forcibly pass; and a verify signal generator for outputting a verify pass signal signaling that the verify operation has passed for each of the plurality of planes.Type: ApplicationFiled: February 20, 2020Publication date: January 28, 2021Applicant: SK hynix Inc.Inventors: Tai Kyu KANG, Chul Woo YANG
-
Patent number: 10851346Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-? and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII.Type: GrantFiled: August 14, 2014Date of Patent: December 1, 2020Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY—ACADEMIC COOPERATION FOUNDATIONInventors: Chul Woo Yang, Mi-La Cho, Sung-Hwan Park, Eun Kyung Kim, Byung Ha Chung, Kyoung-Woon Kim, Seon-Yeong Lee, Sung-Hee Lee, Eun Ji Yang, Jeong-hee Jeong, Min Jung Park, Seok-Jung Kim, Eun-Jung Lee, Su-Jin Moon
-
Patent number: 10716771Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: GrantFiled: June 19, 2019Date of Patent: July 21, 2020Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC CORPORATION FOUNDATIONInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Publication number: 20190328685Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: ApplicationFiled: June 19, 2019Publication date: October 31, 2019Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Patent number: 10369121Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: GrantFiled: August 25, 2014Date of Patent: August 6, 2019Assignee: The Catholic University of Korea Industry-Academic Cooperation FoundationInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Patent number: 10100006Abstract: Provided is a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present subject matter has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.Type: GrantFiled: November 21, 2017Date of Patent: October 16, 2018Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Dong-Yun Shin, Sung-Hwan Park, Chul-Woo Yang, Jong-Young Choi, Min-Jung Park, Hye-Jin Son, Sung-Hee Lee, Seon-Yeong Lee, Eun-Kyung Kim, Jae-Kyung Kim, Seung-Hun Lee, Seong-Hyeok Park
-
Publication number: 20180256519Abstract: The present invention relates to a composition for preventing or treating mitochondrial diseases caused by immunosuppressants, and immune diseases, containing metformin and, more specifically, to a composition for treating mitochondrial diseases caused by immunosuppressants, containing metformin; a pharmaceutical composition for preventing or treating immune diseases, containing, as active ingredients, metformin and an immunosuppressant, which is a target of rapamycin inhibitor (mTOR inhibitor); and a pharmaceutical composite formulation for preventing or treating immune diseases, containing, as ingredients, metformin and a mammalian target of rapamycin inhibitor, wherein the metformin and mammalian target of rapamycin inhibitor are administered simultaneously or separately, or administered in a predetermined sequence.Type: ApplicationFiled: February 23, 2018Publication date: September 13, 2018Inventors: Mi La Cho, Chul Woo Yang, Sung Hwan Park, Seon Yeong Lee, Min Jung Park, Joo Yeon Jhun, Sun Woo Lim, Byung Ha Chung, Eun Kyung Kim, Jae Kyung Kim, Hyun-Sik Na, Se-Young Kim, Eun Jung Lee, Hyeon-Beom Seo
-
Patent number: 10016376Abstract: Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.Type: GrantFiled: December 18, 2015Date of Patent: July 10, 2018Assignee: The Catholic University of Korea Industry-Academic Cooperation FoundationInventors: Mi La Cho, Chul Woo Yang, Jong Young Choi, Sung Hwan Park, Min Jung Park, Seon Yeong Lee, Joo Yeon Jhun, Eun Jung Lee, Jae Kyung Kim, Eun Kyung Kim, Sun Woo Lim
-
Publication number: 20180118668Abstract: The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof.Type: ApplicationFiled: November 21, 2017Publication date: May 3, 2018Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Dong-Yun SHIN, Sung-Hwan PARK, Chul-Woo YANG, Jong-Young CHOI, Min-Jung PARK, Hye-Jin SON, Sung-Hee LEE, Seon-Yeong LEE, Eun-Kyung KIM, Jae-Kyung KIM, Seung-Hun LEE, Seong-Hyeok PARK
-
Publication number: 20170348256Abstract: Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.Type: ApplicationFiled: December 18, 2015Publication date: December 7, 2017Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRYACADEMIC COOPERATION FOUNDATIONInventors: Mi La CHO, Chul Woo YANG, Jong Young CHOI, Sung Hwan PARK, Min Jung PARK, Seon Yeong LEE, Joo Yeon JHUN, Eun Jung LEE, Jae Kyung KIM, Eun Kyung KIM, Sun Woo LIM
-
Publication number: 20170333370Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: ApplicationFiled: August 25, 2014Publication date: November 23, 2017Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Chul-Woo YANG, Dong-Yun SHIN, Min-Jung PARK, Seon-Yeong LEE, Sung-Hee LEE, Eun-Ji YANG, Hye-Jin SON, Eun-Kyung KIM, Jae-Kyung KIM